Choose a location below
UniSC Clinical Trials brings world class clinical research to our local communities. Select a location to view studies in your area.
Sunshine Coast
Our Sippy Downs clinic is within walking distance of the University of the Sunshine Coast's main campus, and partners with various institutions around the Sunshine Coast to provide a range of clinical trials.
Brisbane North and Moreton Bay
Our Morayfield clinic is a dedicated early phase clinical trial facility spanning over 700m2 and specialising in first-in-human research and overnight stays.
Brisbane
Conveniently located in the heart of Brisbane's South Bank business precinct and within walking distance to public transport, our newest clinical trials location offers locals access to phase I through IV clinical trials.
Sunshine Coast Haematology and Oncology Clinic
UniSC Clinical Trials partners with the Sunshine Coast Haematology and Oncology Clinic in Buderim, to bring well needed cancer and haematological disorder clinical trials to the local community.
When available, the results of studies completed by UniSC Clinical Trials are listed below.
| Protocol Number | Protocol | Results Available? |
| 205715 | A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma | |
| 200812 | A Phase III, 4-week, randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI), 'open' triple therapy (FF/VI + UMEC) and dual therapy (FF/VI) in subjects with chronic obstructive pulmonary disease (COPD) | Results Available |
| RTB-101-204 | A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Symptomatic Respiratory Illness Associated with Laboratory-Confirmed Pathogens in the Elderly | Results Pending |
| FBP-001 | A phase I/II study of povidone-iodine nasal spray (“Nasodine”) to investigate safety and tolerability in healthy volunteers (Stage 1), and to investigate safety and efficacy in patients with the common cold (Stage 2). | Results Pending |
| FBP-002 | A phase III study of the safety and efficacy of povidone-iodine nasal spray (“Nasodine”) in the treatment of subjects with the common cold in the natural setting. | Results Pending |
| Protocol Number | Protocol | Results Available? |
| FLU-AUS-1701 | A Prospective Multi-Centre Study of the ellume·lab Flu A+B Test and iTreat Flu A+B Flu Test Performance versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction. | Results Pending |
| RESP16001 | A PROSPECTIVE MULTI-CENTRE STUDY OF THE RESPIRIO FLU TEST AND eLab FLU TEST PERFORMANCE VERSUS REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR) FOR THE RAPID DETECTION OF INFLUENZA A/B. | Results Pending |
| GAS-AUS-1701 | A PROSPECTIVE MULTI-CENTRE STUDY OF THE PERFORMANCE OF THE ELLUME·LAB GROUP A STREP TEST VERSUS CULTURE FOR THE RAPID DETECTION OF GROUP A STREPTOCOCCUS IN PARTICIPANTS WITH ACUTE PHARYNGITIS | Results Pending |
| Protocol Number | Protocol | Results Available? |
| RPC01-3202 | INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | Results Pending |
| GS-US-419-3895 | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease | Results Pending |
| GS-US-419-3896 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease | Study Ongoing |
| GA29144 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | Study Ongoing |
| GA29145 | AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 | Study Ongoing |
| GS-US-418-3898 | Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis | Results Available |
| GS-US-418-3899 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | Results Available |
| Protocol Number | Protocol | Results Available? |
| SHP640-301 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis | Results Available |
| SHP640-303 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis | Results Available |
| P2-868963_001 | A Multicenter, Prospective, Randomized, Double- Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium |
| Protocol Number | Protocol | Results Available? |
| 1002-043 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT | |
| 1245-0167 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF) (EMPERIAL – preserved) | Results Available |
| 1245-0168 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF) (EMPERIAL – reduced) | |
| AROAPOC31001 | A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as well as in Severely Hypertriglyceridemic Patients and Patients with Familial Chylomicronemia Syndrome |
| Protocol Number | Protocol | Results Available? |
| BIVV009-03 | A PHASE 3 PIVOTAL, OPEN-LABEL,MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION | Results Pending |
| BIVV009-04 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION | Study Ongoing |
| Protocol Number | Protocol | Results Available? |
| V160-002 | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age | Results Pending |
| FLU009 | A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over | |
| V199_04 | A Phase IIIb-IV, Multicentre, Randomised, Open-label Study to Characterise the Reactogenicity of Afluria Quad Junior in Children 6 Months to Less Than 3 Years, and Afluria Quad in Children 3 Years to Less Than 9 Years Across Three Influenza Seasons | |
| 2019nCoV-101 | A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-CoV-2 rS) WITH OR WITHOUT MATRIX-M™ ADJUVANT IN HEALTHY SUBJECTS |
|
| V201_01 | A Phase 2, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Ranging Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine |
| Protocol Number | Protocol | Results Available? |
| MT14-AU18GBL208 | Phase II, Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Glabellar Lines | Study Ongoing |
| MT14-AU18LCL209 | Phase , Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Lateral Canthal Lines | Study Ongoing |
| Protocol Number | Protocol | Results Available? |
| ZYN2-CL-005 | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Efficacy and Safety of ZYN002 Administered as a Transdermal Gel to Patients with Knee Pain due to Osteoarthritis | Results Pending |
| Sub-001 | A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy on Pain Reduction and Safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in Adults with Mild to Moderate Osteoarthritis of the Knee | Results Pending |
| Protocol Number | Protocol | Results Available? |
| ZYN2-CL-03 | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures, Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy (STAR 1) | Results Pending |
| ZYN2-CL-004 | Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2) | Results Pending |
| Protocol Number | Protocol | Results Available? |
| Nexvax2-1005 | A BIOEQUIVALENCE STUDY OF NEXVAX2 IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE | |
| Nexvax2-2006 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE TO ASSESS THE EFFECT OF NEXVAX2 ON SYMPTOMS AFTER MASKED GLUTEN FOOD CHALLENGE | |
| CDX6114-002 | A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients with Phenylketonuria (PKU). |
| Protocol Number | Protocol | Results Available? |
| ML-004-ER-001 | A PHASE 1 OPEN LABEL CROSSOVER STUDY OF ML-004-ER UNDER FASTED AND FED CONDITIONS IN ADULT HEALTHY VOLUNTEERS |
Results Pending |
Clinical Trial Partner Sites
UniSC Clinical Trials works with partner sites that run separate, specialised studies. These studies are not administered by UniSC Clinical Trials. Please contact the site directly if you are interested in one of these studies.
VasoActive Research Group
The Foot-PAD Trial
Does leg artery disease cause you pain when walking?
If you are over 18 years of age and suffer symptoms of peripheral artery disease (PAD) you may be eligible to take part in a trial. The Foot-PAD Trial is testing a new therapy for PAD using a footplate muscle stimulation device.
The trial will involve nine study visits across an 18-week period (including walking tests, vascular function tests and questionnaires) and daily home use of a Revitive footplate device for 12 weeks. Participants will receive expenses to cover cost of travel to study visits (up to $50 per visit), a free Revitive Medic Coach device to keep upon completion of the trial (RRP $550) and a medical screening.
All study appointments will be held at the University of the Sunshine Coast Sippy Downs campus.
Protocol Title: The Foot-PAD trial: Effect of a footplate muscle stimulation program on walking capacity in people with Peripheral Artery Disease.
HREC approval: The Prince Charles Hospital Human Research Ethics Committee / USC Human Research Ethics Committee.
Coast Joint Care - Rheumatology Research Unit
To see if you are eligible for these studies, please call the Rheumatology Research Unit on 07 5443 1033.
Knee Osteoarthritis Study
We are looking for volunteers who:
- Are between 40 to 75 years of age
- Have been diagnosed with osteoarthritis of the knee
- Have persisting pain in the knee despite current medications
To participate in a clinical trial for a potential new treatment for knee osteoarthritis.
This is a 5-year study and participants will be required to attend regular on-site visits to our Maroochydore clinic over this period.
For further information or to register your interest, please call the Rheumatology Research Unit on 07 5443 1033.
Full title: A 5-year, randomized, double-blind, placebo-controlled, multi-centre study assessing the efficacy, safety and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis.
HREC Approval: Bellberry Human Research Ethics Committee
As a clinical trials participant, your safety and comfort are our highest priorities. We are committed to keeping you informed throughout the entire clinical trial experience, so you can make informed decisions about the management of your health.
This includes:
- An informed consent process, where all relevant information is provided to you prior to making a decision.
- The opportunity for an in-depth discussion with your health provider (for example, GP or specialist) as well as the medical researchers undertaking the trial, before you commence the trial.
- The ability to leave a clinical trial at any time, with no obligation to remain in a trial if you no longer wish to participate.
- The ability to discuss results from any tests performed.
- A summary of the results at the completion of the trial.
Common questions about clinical trials
Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your local doctor. Ask questions about anything that you do not understand or want to know more about. A participant information sheet or consent form will be provided to you and tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the research. Participation in research is voluntary. If you do not wish to take part, you do not have to. You will receive the best possible care whether or not you take part.
All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). Projects carried out by UniSC will be conducted according to the National Statement on Ethical Conduct in Human Research (2007). This statement has been developed to protect the interests of people who agree to participate in human research studies.
A placebo is a medication with no active ingredients or a procedure without any medical benefit. It looks like the real thing but it is not. This research project has been designed to make sure the researchers interpret the results in a fair and appropriate way and avoids study doctors or participants jumping to conclusions.
We cannot guarantee or promise that you will receive any benefits from clinical research. For further information please read the Consumer Guide to Clinical Trials.
Medical treatments often cause side effects. You may have none, some or all of the effects listed for a specific clinical trial, and they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk with your study doctor. Your study doctor will also be looking out for side effects.
If you suffer any injuries or complications as a result of the research project, you should contact the study team as soon as possible and you will be assisted with arranging appropriate medical treatment. If you are eligible for Medicare, you can receive any medical treatment required to treat the injury or complication, free of charge, as a public patient in any Australian public hospital.
There are no additional costs associated with participating in a research project, nor will you be paid. All medication, tests and medical care required as part of the research project will be provided to you free of charge. You may be reimbursed for any reasonable travel, parking, meals and other expenses associated with the research project visit.
Participation in any research project is voluntary. If you do not wish to take part, you do not have to. If you decide to take part and later change your mind, you are free to withdraw from the project at any stage.
More information
The National Health and Medical Research Council and the Department of Industry and Science have developed a Consumer Guide to Clinical Trials, which provides general information about clinical trials for consumers, health care providers, researchers and industry.
This information has been made available with permission from the Consumer Health Forum of Australia.
Established in 2014, UniSC Clinical Trials is delivering ethical, expert research across a range of therapeutic areas. Working with a network of qualified medical practitioners in public, private and independent practices, we aim to create a hub of clinical research capabilities across the Sunshine Coast, Brisbane and Moreton Bay regions, and increase the therapeutic options available to clinicians and their patients.
Referring patients
We encourage all trial participants to maintain routine visits with their referring physician, and are committed to the timely and effective sharing of progress reports and health outcomes.
To discuss a patient’s eligibility or for more information please contact us.
Work with us
Each clinical trial requires an expert and committed team, including:
- The Principal Investigator, who is accountable for the conduct of the trial, recruitment and safety of all participants
- Co-Investigator(s), who are medically qualified and provide medical support and expertise to the principal investigator
- Clinical research coordinator(s) who are trained in clinical research (from a nursing, science, pharmacy or health-related background) and provide project management, recruitment and administrative support
We welcome expressions of interest from medically qualified individuals who are experienced or specialising in a specific therapeutic area, and are interested in partnering on a clinical trial. The USC Clinical Trials can provide full training and certification in GCP (online) and meet any other clinical trial training needs.
If you are a clinical trial professional, coordinator or trainee please get in touch to express your interest in working with us.